Ultragenyx Cuts 130 Jobs After Setrusumab Fails; VERAXA Shareholders OK Financing Changes
Jul 27, 2026
Ultragenyx cuts 10% of staff after setrusumab Phase III misses; VERAXA Biotech shareholders approve capital and board changes at EGM.
News Related to setrusumab
Related coverage linked through entity extraction aliases.
Two Securities Class Action Lawsuits Filed Against Biopharmaceutical Companies Over Alleged Clinical Trial Misstatements
Jun 11, 2026
Two securities class action lawsuits have been filed against NASDAQ-listed biopharmaceutical companies Ultragenyx and Vistagen. Both cases allege defendants made misleading statements about clinical trial results for key drug programs. Investors face deadlines in March and April 2026 to request lead plaintiff status.
Ultragenyx launches restructuring plan as class action targets setrusumab disclosures
Apr 04, 2026
Ultragenyx began a restructuring plan that includes a 10% workforce reduction and termination of UX143 manufacturing agreements. The company also faces a class action tied to setrusumab disclosures.
Class Action Lawsuits Filed Against Atara, Ultragenyx, Mereo, and Vistagen Over Alleged Misstatements
Mar 28, 2026
Class action lawsuits allege false statements about clinical trial results and regulatory prospects at Atara Biotherapeutics, Ultragenyx, Mereo BioPharma, and Vistagen Therapeutics. The complaints cite failed Phase 3 studies for setrusumab in Osteogenesis Imperfecta and fasedienol for social anxiety disorder, along with manufacturing issues affecting Atara's tabelecleucel application. Investors have deadlines ranging from April to May 2026 to seek lead plaintiff status.
Ultragenyx Faces Lawsuits Over Trial Data as UX111 Gene Therapy Advances
Feb 17, 2026
Ultragenyx Pharmaceutical confronts multiple shareholder class action lawsuits over Phase III trial disclosures while reporting positive UX111 gene therapy data and implementing a 10% workforce reduction.
Ultragenyx Faces Securities Class Action After Phase 3 Setrusumab Trial Failures
Dec 30, 2025
Ultragenyx Pharmaceutical faces federal securities class action lawsuits following the failure of Phase 3 Orbit and Cosmic studies for setrusumab in Osteogenesis Imperfecta, with stock falling over 42% after December 2025 results announcement.